Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals, Inc. ANIP
$72.58 +0.55% Close, Oct 5, 2026 · NASDAQ · Market cap $1.64B
High qualityInexpensive vs sectorLow risk
Next earnings report: Nov 6, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to 15.3% from 2.0% a year earlier.
- At 15.7× trailing earnings, the shares trade at the lowest P/E of the company's past five years.
- Earnings beat analyst estimates in each of the last 14 quarters (average surprise over the last four: +25.7%).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 24%
- FCF growth (TTM, YoY)Top 28%
- Revenue growth, 3-year CAGRTop 16%
- Revenue growth accelerationBottom 23%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 15%
- Gross marginTop 49%
- Operating marginTop 18%
- Cash conversion (OCF / net income)Top 39%
- Accruals (lower is better)Bottom 45%
- Net debt / EBITDA (lower is better)Top 31%
- Interest coverTop 25%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 7%
- Free-cash-flow yieldTop 8%
- EBITDA / enterprise valueTop 4%
- Sales / enterprise valueTop 20%
- P/E vs own 5-year history (lower is better)Top 5%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 24%
- 6-month returnBottom 36%
- 1-year return vs S&P 500Bottom 30%
- Distance from 52-week highTop 39%
- Trend checklist (0–4)Bottom 13%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 20%
- Consecutive EPS beatsTop 2%
- Share of analysts rating BuyBottom 25%
- Upside to consensus price targetBottom 40%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 9%
- Maximum drawdown, 3 yearsTop 4%
- Beta vs S&P 500 (lower is better)Top 15%
- Net debt / EBITDA (lower is better)Top 31%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 37.0% | 30.9% | ↓ |
| Gross margin | 61.1% | 65.2% | ↑ |
| Operating margin | 2.0% | 15.3% | ↑ |
| FCF margin | 14.1% | 16.3% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 30.9% | 37.0% | ↓ | Top 24% |
| Gross margin | 65.2% | 61.1% | ↑ | Top 49% |
| Operating margin | 15.3% | 2.0% | ↑ | Top 18% |
| Net margin | 10.8% | -1.4% | ↑ | — |
| Free-cash-flow margin | 16.3% | 14.1% | ↑ | — |
| Return on invested capital | 9.3% | — | Top 15% | |
| Revenue growth, 3-year CAGR | 40.8% | — | Top 16% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.79×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -5.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 4.2%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -9.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.12×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 5.5×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.60%
- Shareholder yield
- 0.60%
- Share count change, 1 year
- +7.9%
- Share count change, 3-year CAGR
- +7.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 7, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 14
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +25.7%
- Average 2-day reaction, last 8
- +2.2%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $99.50
- Target vs current price
- +37.1%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 60%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 7, 2026 | +8.3% | -5.3% | -9.5% | -12.9% | — |
| May 8, 2026 | +60.2% | -2.4% | -5.2% | -3.3% | -5.6% |
| Feb 27, 2026 | +17.1% | -4.2% | -2.0% | -3.9% | +7.2% |
| Nov 7, 2025 | +17.2% | +0.2% | -6.3% | -9.4% | -9.9% |
| Aug 8, 2025 | +30.4% | +18.1% | +30.4% | +38.2% | +31.3% |
| May 9, 2025 | +24.1% | -7.3% | -16.8% | -13.4% | -7.9% |
| Feb 28, 2025 | +15.6% | +13.4% | +11.9% | +25.2% | +5.9% |
| Nov 8, 2024 | +22.9% | +5.2% | +0.9% | -2.4% | +3.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 7, 2026 | $2.21 | $2.04 | +8.3% | $266.0M |
| May 8, 2026 | $2.05 | $1.28 | +60.2% | $237.5M |
| Feb 27, 2026 | $2.33 | $1.99 | +17.1% | $247.1M |
| Nov 7, 2025 | $2.04 | $1.74 | +17.2% | $227.8M |
| Aug 8, 2025 | $1.80 | $1.38 | +30.4% | $211.4M |
| May 9, 2025 | $1.70 | $1.37 | +24.1% | $197.1M |
| Feb 28, 2025 | $1.63 | $1.41 | +15.6% | $190.6M |
| Nov 8, 2024 | $1.34 | $1.09 | +22.9% | $148.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 15.7× | 45.8× | 0th | Top 7% |
| P/E (forward) | 7.8× | — | — | — |
| EV / EBITDA | 6.3× | — | — | Top 4% |
| EV / Sales | 1.65× | — | — | Top 20% |
| Free-cash-flow yield | 9.72% | — | — | Top 8% |
| Earnings yield | 6.38% | — | — | Top 7% |
P/E over the past five years
Range 16.9× – 88.7× since Sep 30, 2023. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -4.3%
- 200-day average slope (20 days)
- -1.1%
- Distance from 50-day average
- -3.5%
- Distance from 200-day average
- -7.5%
- RSI (14)
- 44.9
- Relative volume
- 0.73×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 30.0%
- Volatility vs own 5-year history
- 11th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.47
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -23.9%
- Maximum drawdown, 3 years
- -29.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 2, 2021 | Jun 16, 2022 | -59.4% | 156 days | 287 days (Aug 9, 2023) |
| May 7, 2021 | Aug 19, 2021 | -31.4% | 72 days | 49 days (Oct 28, 2021) |
| Sep 15, 2025 | Sep 11, 2026 | -29.0% | 249 days | Not yet recovered |
| Nov 3, 2023 | Dec 6, 2023 | -25.5% | 22 days | 57 days (Feb 29, 2024) |
| Mar 27, 2024 | Dec 20, 2024 | -23.4% | 186 days | 84 days (Apr 25, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.64B
- P/E (TTM)
- 15.7
- EPS, diluted (TTM)
- $4.63
- Revenue (TTM)
- $978.4M
- 52-week range
- $69.58 – $97.00
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $216.1M | $316.4M | $486.8M | $614.4M | $883.4M |
| Gross profit | $115.5M | $177.6M | $305.3M | $364.2M | $450.6M |
| Operating income | -$39.8M | -$35.3M | $47.0M | $584,000 | $81.2M |
| Net income | -$42.6M | -$47.9M | $18.8M | -$18.5M | $78.3M |
| EPS (diluted) | -$3.40 | -$3.05 | $0.94 | -$1.04 | $3.32 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $148.3M | $190.6M | $197.1M | $211.4M | $227.8M | $247.1M | $237.5M | $266.0M |
| Net income | -$24.2M | -$10.3M | $15.7M | $8.5M | $24.1M | $27.5M | $29.5M | $24.7M |
| EPS (diluted) | -$1.27 | -$0.55 | $0.69 | $0.36 | $1.13 | $1.17 | $1.28 | $1.05 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $3.3M | -$31.2M | $119.0M | $64.0M | $185.2M |
| Capital expenditure | -$23.6M | -$16.5M | -$18.5M | -$17.0M | -$34.3M |
| Free cash flow | -$20.3M | -$47.7M | $100.4M | $47.1M | $150.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $68.7M | -$2.0M | $75.6M | -$11.0M | $1.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $375.9M
- Total assets
- $1.49B
- Total liabilities
- $896.9M
- Total debt
- $330.3M
- Net debt
- -$29.9M
- Shareholders’ equity
- $597.2M
As of Jun 30, 2026 (filed Aug 7, 2026).
Short interest
- Shares sold short
- 2,490,166
- Days to cover
- 7.44
- Change vs previous report
- -26.0%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 18, 2013
- 1-for-6
- Jun 4, 2012
- 1-for-6
- Jun 3, 2002
- 1-for-10